A Phase Ⅲ Clinical Study of SNA02-48 Injection
2026年6月2日 更新者:Sinovac Life Sciences Co., Ltd.
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of SNA02-48 Injection in Populations With High-Risk Tetanus Exposure
The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.
研究概览
研究类型
介入性
注册 (估计的)
600
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Chuanlin Wang, MD
- 电话号码:+86 13911883012
- 邮箱:wangchuanlinvip@163.com
学习地点
-
-
Anhui
-
Fuyang、Anhui、中国、236699
- Taihe County People's Hospital
-
Hefei、Anhui、中国、230601
- The Second Affiliated Hospital of Anhui Medical University
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- Peking University First Hospital
-
Beijing、Beijing Municipality、中国、100044
- Peking University People's Hospital
-
Beijing、Beijing Municipality、中国、100730
- Peking Union Medical College Hospital
-
Beijing、Beijing Municipality、中国、100070
- Beijing Tiantan Hospital affiliated to Capital Medical University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou、Guangdong、中国、510150
- The Third Affiliated Hospital of Guangzhou Medical University
-
Guangzhou、Guangdong、中国、510900
- The Fifth Affiliated Hospital of Southern Medical University
-
Guangzhou、Guangdong、中国、510440
- Guangzhou Eighth People's Hospital, Guangzhou Medical University
-
Shenzhen、Guangdong、中国、518025
- Shenzhen Second People's Hospital
-
Shenzhen、Guangdong、中国、518100
- Longhua District People's Hospital of Shenzhen
-
-
Guangxi
-
Liuzhou、Guangxi、中国、545000
- Liuzhou Worker's Hospital
-
Liuzhou、Guangxi、中国、545200
- Liuzhou People's Hospital
-
-
Guizhou
-
Zunyi、Guizhou、中国、563000
- Affiliated Hospital of Zunyi Medical University
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050000
- The Second Hospital of Hebei Medical University
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Wuhan Union Hospital
-
-
Hunan
-
Hengyang、Hunan、中国、421010
- Affiliated Nanhua Hospital, University of South China
-
-
Jiangsu
-
Taizhou、Jiangsu、中国、225300
- Taizhou People's Hospital
-
Yangzhou、Jiangsu、中国、225000
- Affiliated Hospital of Yangzhou University
-
Zhenjiang、Jiangsu、中国、212013
- Affiliated Hospital of Jiangsu University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330008
- The Second Affiliated Hospital of Nanchang University
-
Pingxiang、Jiangxi、中国、337000
- Pingxiang People's Hospital
-
-
Shandong
-
Weifang、Shandong、中国、261000
- Weifang People's Hospital
-
-
Shanxi
-
Linfen、Shanxi、中国、041000
- Linfen Central Hospital
-
Taiyuan、Shanxi、中国、030032
- Shanxi Bethune Hospital
-
Yuncheng、Shanxi、中国、044099
- Yuncheng Central Hospital, Shanxi Province
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Lishui、Zhejiang、中国、323020
- Lishui Central Hospital
-
Ningbo、Zhejiang、中国、315000
- Ningbo Medical Center Li HuiLi Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Males or females aged 18 years and above;
- Participants who can understand and voluntarily sign the informed consent form;
- Participants with high-risk tetanus exposure;
- Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures from the time the participant signs the informed consent form until 6 months after administration, with no plans for sperm or egg donation.
Exclusion Criteria:
- Suspected or confirmed tetanus ;
- A history of previous tetanus infection;
- A known history of 3 or more doses of tetanus toxoid or vaccines containing tetanus toxoid, or fewer than 3 previous doses but with the last dose of tetanus toxoid or vaccines containing tetanus toxoid administered within 6 months prior to the administration of the investigational product;
- Known hypersensitivity to the investigational product (including excipients, HTIG, and other therapeutic monoclonal antibodies), or suffering from severe allergic diseases that, in the investigator's judgment, may impair the participant's safety; Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:人破伤风免疫球蛋白 (HTIG)
如果随机分配至 HTIG,参与者将接受单次肌内注射 HTIG
|
IM gluteal injection
|
|
实验性的:SNA02-48
If randomized to SNA02-48, participant will receive a single IM gluteal injection of SNA02-48
|
IM gluteal injection
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The proportion of participants with an increase of anti-tetanus neutralizing antibody titers (∆ titers) over protective level.
大体时间:Baseline up to 12 hours after receipt of study drug
|
Baseline up to 12 hours after receipt of study drug
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The incidence of tetanus
大体时间:Up to 105 days after receipt of study drug
|
Up to 105 days after receipt of study drug
|
|
anti-tetanus neutralizing antibody titers
大体时间:Up to 90 days after receipt of study drug
|
Up to 90 days after receipt of study drug
|
|
Incidence of adverse events
大体时间:Up to 105 days after receipt of study drug
|
Up to 105 days after receipt of study drug
|
|
Incidence of severe adverse events (SAEs)
大体时间:Up to 105 days after receipt of study drug
|
Up to 105 days after receipt of study drug
|
|
To evaluate the plasma concentration of SNA02-48
大体时间:Up to 90 days after receipt of study drug
|
Up to 90 days after receipt of study drug
|
|
Incidence of anti-drug antibody (ADA) and neutralizing antibody (Nab)
大体时间:Up to 90 days after receipt of study drug
|
Up to 90 days after receipt of study drug
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年6月28日
初级完成 (估计的)
2027年3月31日
研究完成 (估计的)
2027年5月31日
研究注册日期
首次提交
2026年6月2日
首先提交符合 QC 标准的
2026年6月2日
首次发布 (实际的)
2026年6月8日
研究记录更新
最后更新发布 (实际的)
2026年6月8日
上次提交的符合 QC 标准的更新
2026年6月2日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.